Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients

被引:66
作者
Danila, Daniel C. [1 ,2 ]
Samoila, Aliaksandra [3 ]
Patel, Chintan [3 ]
Schreiber, Nicole [1 ]
Herkal, Amrita [3 ]
Anand, Aseem [1 ,5 ]
Bastos, Diogo [1 ]
Heller, Glenn [4 ]
Fleisher, Martin [3 ]
Scher, Howard I. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, Dept Med, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA
[5] Lund Univ, Dept Translat Med, Div Urol Cancers, Malmo, Sweden
关键词
AdnaTest; biomarkers; CellSearch; circulating tumor cells; prostate cancer; prostate-specific markers; ABIRATERONE; SYSTEM; AR-V7;
D O I
10.1097/PPO.0000000000000220
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Circulating tumor cell (CTC) number measured with the CellSearch assay is prognostic for survival in metastatic castration-resistant prostate cancer before and after therapy. Using a standard operating protocol for sample collection, processing, and analysis, we compared detection rates of CellSearch performed using US Food and Drug Administration-cleared methodology with a second positive selection assay, AdnaTest, and a nonselection polymerase chain reaction (PCR)-based (direct detection PCR [DDPCR]) assay in 55 blood samples from 47 men with progressive metastatic castration-resistant prostate cancer. AdnaTest requires processing within 4 hours of the draw and detects KLK3, PSMA, and EGFR transcripts in cells captured on magnetic beads. The DDPCR assay can be processed up to 7 days after a draw and detects KLK2, KLK3, HOXB13, GRHL2, and FOXA1 genes. AdnaTest and DDPCR were considered positive if at least 1 transcript was detected. AdnaTest detected CTCs in 34 samples (62%; 95% confidence interval [CI], 48%-75%), of which 23 (68%) had unfavorable CTC counts by CellSearch. A positive DDPCR result was seen in 38 cases (69%; 95% CI, 55%-81%), including 24 (63%) with unfavorable CellSearch CTC counts. CellSearch found unfavorable CTC counts in 25 samples (45%; 95% CI, 33%-58%). Sensitivities were similar between the AdnaTest and DDPCR assays, and both were more sensitive than CellSearch. Concordance probability estimates (possible values, 0.5-1.0) associating the biomarker result with survival were similar: 0.77 (SE, 0.07) for AdnaTest, 0.72 (SE, 0.08) for DDPCR, and 0.76 (SE, 0.06) for CellSearch. Overall detection rates between the AdnaTest and DDPCR assays were similar, and both were superior to CellSearch. The DDPCR assay required the lowest blood volume, least on-site processing, and longest stability for batch processing.
引用
收藏
页码:315 / 320
页数:6
相关论文
共 22 条
  • [1] Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
    Allard, WJ
    Matera, J
    Miller, MC
    Repollet, M
    Connelly, MC
    Rao, C
    Tibbe, AGJ
    Uhr, JW
    Terstappen, LWMM
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (20) : 6897 - 6904
  • [2] Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system
    Andreopoulou, E.
    Yang, L. -Y.
    Rangel, K. M.
    Reuben, J. M.
    Hsu, L.
    Krishnamurthy, S.
    Valero, V.
    Fritsche, H. A.
    Cristofanilli, M.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (07) : 1590 - 1597
  • [3] Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Luber, Brandon
    Wang, Hao
    Chen, Yan
    Nakazawa, Mary
    Nadal, Rosa
    Paller, Channing J.
    Denmeade, Samuel R.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Luo, Jun
    [J]. JAMA ONCOLOGY, 2015, 1 (05) : 582 - 591
  • [4] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Wang, Hao
    Luber, Brandon
    Nakazawa, Mary
    Roeser, Jeffrey C.
    Chen, Yan
    Mohammad, Tabrez A.
    Chen, Yidong
    Fedor, Helen L.
    Lotan, Tamara L.
    Zheng, Qizhi
    De Marzo, Angelo M.
    Isaacs, John T.
    Isaacs, William B.
    Nadal, Rosa
    Paller, Channing J.
    Denmeade, Samuel R.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Luo, Jun
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) : 1028 - 1038
  • [5] Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer
    Danila, Daniel C.
    Heller, Glenn
    Gignac, Gretchen A.
    Gonzalez-Espinoza, Rita
    Anand, Aseem
    Tanaka, Erika
    Lilja, Hans
    Schwartz, Lawrence
    Larson, Steven
    Fleisher, Martin
    Scher, Howard I.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (23) : 7053 - 7058
  • [6] Analytic and Clinical Validation of a Prostate Cancer-Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival
    Danila, Daniel C.
    Anand, Aseem
    Schultz, Nikolaus
    Heller, Glenn
    Wan, Mingliang
    Sung, Clifford C.
    Dai, Charles
    Khanin, Raya
    Fleisher, Martin
    Lilja, Hans
    Scher, Howard I.
    [J]. EUROPEAN UROLOGY, 2014, 65 (06) : 1191 - 1197
  • [7] Circulating Tumors Cells as Biomarkers Progress Toward Biomarker Qualification
    Danila, Daniel C.
    Pantel, Klaus
    Fleisher, Martin
    Scher, Howard I.
    [J]. CANCER JOURNAL, 2011, 17 (06) : 438 - 450
  • [8] TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate
    Danila, Daniel C.
    Anand, Aseem
    Sung, Clifford C.
    Heller, Glenn
    Leversha, Margaret A.
    Cao, Long
    Lilja, Hans
    Molina, Arturo
    Sawyers, Charles L.
    Fleisher, Martin
    Scher, Howard I.
    [J]. EUROPEAN UROLOGY, 2011, 60 (05) : 897 - 904
  • [9] Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
    de Bono, Johann S.
    Scher, Howard I.
    Montgomery, R. Bruce
    Parker, Christopher
    Miller, M. Craig
    Tissing, Henk
    Doyle, Gerald V.
    Terstappen, Leon W. W. M.
    Pienta, Kenneth J.
    Raghavan, Derek
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6302 - 6309
  • [10] Concordance probability and discriminatory power in proportional hazards regression
    Gönen, M
    Heller, G
    [J]. BIOMETRIKA, 2005, 92 (04) : 965 - 970